SCHEMBL4669231

SCHEMBL4669231

c1ccc(C(OCCCOC(c2ccccc2)c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 4/20 0.61
SLC6A4 P31645 4/20 0.61
SLC6A3 Q01959 4/20 0.61
SCN1A P35498 3/20 0.61
SCN2A Q99250 3/20 0.61
SCN3A Q9NY46 3/20 0.61
LMNA P02545 2/20 0.61
HTT P42858 2/20 0.61
KCNH2 Q12809 2/20 0.61
HRH4 Q9H3N8 2/20 0.61
CYP1A2 P05177 2/20 0.61
CYP2D6 P10635 2/20 0.61
TSHR P16473 2/20 0.61
THPO P40225 2/20 0.61
CHRM2 P08172 1/20 0.61
CHRM4 P08173 1/20 0.61
CHRM5 P08912 1/20 0.61
ADRA2A P08913 1/20 0.61
CHRM1 P11229 1/20 0.61
ADRA2B P18089 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4670218 0.95 SCN1A (0.61) SLC6A2SLC6A4SLC6A3SCN1ASCN2A
SCHEMBL4667564 0.90 SCN1A (0.65) SLC6A2SLC6A4SLC6A3SCN1ASCN2A
SCHEMBL14380220 0.89 SCN1A (0.52) SLC6A2SLC6A4SLC6A3SCN1ASCN2A
SCHEMBL14160114 0.88 SCN1A (0.55) SLC6A2SLC6A4SLC6A3SCN1ASCN2A
SCHEMBL14160145 0.87 HTR2A (0.53) SLC6A2SLC6A4SLC6A3SCN1ASCN2A
SCHEMBL6976130 0.87 SLC6A2 (0.53) SLC6A2SLC6A4SLC6A3SCN1ASCN2A
SCHEMBL10356352 0.87 SCN1A (0.53) SLC6A2SLC6A4SLC6A3SCN1ASCN2A
SCHEMBL7949004 0.87 SCN1A (0.53) SLC6A2SLC6A4SLC6A3SCN1ASCN2A
SCHEMBL4667514 0.87 SCN1A (0.53) SLC6A2SLC6A4SLC6A3SCN1ASCN2A
SCHEMBL3333232 0.87 SCN1A (0.53) SLC6A2SLC6A4SLC6A3SCN1ASCN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1930308-A1 Pharmaceutical agents for the treatment of cerebral amyloidosis NYMOX CORPORATION (CA) 2008-06-11 EP disclosed
EP-1930308-A1 Pharmaceutical agents for the treatment of cerebral amyloidosis NYMOX CORPORATION (CA) 2008-06-11 EP disclosed
EP-0983222-B1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORP (CA) 2007-11-28 EP disclosed
EP-0983222-B1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORP (CA) 2007-11-28 EP disclosed
EP-0983222-A1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORPORATION (CA) 2000-03-08 EP disclosed
WO-1998052898-A9 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORP (CA) 1999-04-01 WO disclosed
WO-1998052898-A1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORPORATION (CA) 1998-11-26 WO disclosed